

MOLECULE HOLDINGS INC.

(formerly Everton Resources Inc.)

Management's Discussion and Analysis

For the years ended October 31, 2020 and 2019

Molecule Holdings Inc. (formerly Everton Resources Inc.)

Management's Discussion & Analysis

For the years ended October 31, 2020 and 2019

This Management's Discussion and Analysis ("MD&A") for Molecule Holdings Inc. (formerly Everton Resources Inc.) (the "Company" or "Molecule Holdings") should be read in conjunction with the consolidated financial statements for the years ended October 31, 2020 and 2019 and the notes thereto.

The financial information in this MD&A is derived from the Company's consolidated financial statements for the years ended October 31, 2020 and 2019, which were prepared in accordance with International Financial Reporting Standards ("IFRS"). The effective date of this MD&A is February 18, 2021.

CAUTION REGARDING FORWARD-LOOKING STATEMENTS

Certain information contained in this document may contain "forward-looking statements". Forward-looking statements may include, among others, statements regarding the Company's future plans, costs, objectives, economic performance, or the assumptions underlying any of the foregoing. In this document, words such as "may", "would", "could", "will", "likely", "believe", "expect", "anticipate", "intend", "plan", "estimate" and similar words and the negative form thereof are used to identify forward-looking statements. Forward-looking statements should not be read as guarantees of future performance or results and will not necessarily be accurate indications of whether such future performance will be achieved. Forward-looking statements are based on information available at the time and/or management's good faith belief with respect to future events and are subject to known or unknown risks, uncertainties and other unpredictable factors, many of which are beyond the Company's control. These risks and uncertainties include, but are not limited to, those described under the headings "Risk Management and Capital Management" and "Inherent Risk Factors" in this MD&A and could cause actual events or results to differ materially from those projected in any forward-looking statements. The Company does not intend, nor does it undertake any obligation, to update or revise any forward-looking statements contained in this MD&A to reflect subsequent information, events or circumstances or otherwise, except if required by applicable law.

BUSINESS OVERVIEW

Molecule Holdings Inc. (formerly Everton Resources Inc.) was incorporated under the Business Corporations Act (Alberta) on November 7, 1996.

On September 16, 2020, the Company completed a reverse takeover transaction (the "Transaction"), pursuant to which it acquired all of the issued and outstanding common shares (the "OpCo Shares") of the privately held Molecule Inc. ("OpCo"). The Company has changed the nature of its operations to the business of OpCo, which is now a wholly owned subsidiary of the Company, being the production and co-packing of cannabis-infused beverages. On February 28, 2020, OpCo was issued a Standard Processing Licence by Health Canada (the "Licence") in accordance with the Cannabis Act and Cannabis Regulations. The Licence authorizes OpCo to: possess cannabis; produce cannabis, other than obtaining it by cultivating, propagating or harvesting it; and to sell cannabis in accordance with subsection 17(5) of the Cannabis Regulations and in accordance with the conditions of the Licence.

As part of the Transaction and prior to the completion of the Arrangement (as defined below), the Company changed its name to "Molecule Holdings Inc."

The address of the Company's corporate office is 591 Reynolds Road, Lansdowne, Ontario K0E 1L0. Molecule Holdings' common shares are listed for trading on the Canadian Securities Exchange ("CSE") under the symbol "MLCL".

The Transaction

The Company and OpCo completed the Transaction by way of plan of arrangement (the "Arrangement") pursuant to the terms of an arrangement agreement dated November 27, 2019, as amended (the "Arrangement Agreement"), whereby the Company acquired all of the issued and outstanding OpCo Shares in exchange for the same number of Common Shares. Pursuant to the terms of the Arrangement Agreement,

Molecule Holdings Inc. (formerly Everton Resources Inc.)

Management's Discussion & Analysis

For the years ended October 31, 2020 and 2019

an aggregate 74,700,100 Common Shares were issued to the former shareholders of OpCo. An additional 1,215,500 Common Shares (the "Debt Shares") were issued to a director of the Company as contemplated in the Arrangement Agreement, as settlement of debt. With the completion of the Transaction and the issuance of the Debt Shares, the Company had 85,229,047 Common Shares issued and outstanding on the Listing Date (on an undiluted basis), in addition to the Preferred Shares (as defined below).

Preferred Share Issuance

Pursuant to the terms of the Arrangement Agreement, the Company created and issued 9,313,447 preferred shares (the "Preferred Shares"). The purpose of the Preferred Shares is to provide the shareholders of the Company other than original OpCo shareholders with a right to receive, on a pro rata basis, an economic benefit, subject to an aggregate maximum of up to \$500,000, in the event that any of the Company's remaining mining royalties are triggered and generate revenue within a maximum period of five (5) years from the date of the issuance of the Preferred Shares. The Preferred Shares provide that, if triggered, the Preferred Shares will be redeemable, on a pro rata basis, for cash up to an aggregate maximum of \$500,000. The Preferred Shares do not otherwise have any rights or recourses. As these royalties relate to properties with no verified resources and as no other triggering event has occurred, the Preferred Shares are valued at \$Nil in the consolidated financial statements.

Going Concern

The consolidated financial statements have been prepared on a going concern basis, which assumes that the Company will be able to realize its assets and discharge its liabilities in the normal course of operations for the foreseeable future. As at October 31, 2020, the Company had not yet generated any revenue from operations. The Company has no income or cash inflow from operations, has incurred losses since its inception and has limited working capital. These conditions indicate the existence of material uncertainties that may cast significant doubt about the Company's ability to continue as a going concern. Continued operation of the Company is dependent on achieving commercial operations, which requires continued financial support through equity and/or debt financings, or the achievement of profitable operations in the future. Management is evaluating alternatives to secure additional financing so that the Company can continue to operate as a going concern. Nevertheless, there is no assurance that these initiatives will be successful or sufficient. These financial statements do not include any adjustments to the carrying value of assets and liabilities and the reported expenses and statement of financial position classifications that would be necessary should the Company be unable to continue as a going concern and these adjustments could be material.

CORPORATE DEVELOPMENT HIGHLIGHTS

CLOSING OF PRIVATE PLACEMENTS AND OTHER FINANCING

FISCAL 2019

On September 28, 2018, on incorporation of the Company, 100 class B common shares were issued for total consideration of \$1. These were the only class B common shares to have been issued and were identical in all respects to the class A common shares.

On November 30, 2018, the Company closed a private placement for gross proceeds of \$25,000. The private placement was comprised of 5,000,000 shares at a price of \$0.005 per share. A Director of the Company participated in the private placement for a total amount of \$15,000.

In December 2018, the Company closed a private placement for gross proceeds of \$684,772. The private placement was comprised of 13,695,433 shares at a price of \$0.05 per share. A Director of the Company participated in the private placement for an amount of \$34,772.

Molecule Holdings Inc. (formerly Everton Resources Inc.)

Management's Discussion & Analysis

For the years ended October 31, 2020 and 2019

In March/April 2019, the Company closed a private placement for gross proceeds of \$3,730,000. The private placement was comprised of 37,300,000 shares at a price of \$0.10 per share. A Director of the Company participated in the private placement for an amount of \$50,000.

Under shares for debt agreements, the Company issued 5,000,000 shares on November 30, 2018 in settlement of \$25,000 in debt, 1,304,567 shares in December 2018 in settlement of \$65,228 in debt and 200,000 shares in April 2019 in settlement of \$20,000 in debt. In total, the Company issued 6,504,567 shares in settlement of \$110,228 in debt. Officers and Directors received a total of 5,304,567 shares in settlement of \$85,228 in debt.

On June 13, 2019, the Company acquired all of the issued and outstanding shares of Burrard Bay Capital Corp. ("Burrard Bay") by issuing 10,000,000 common shares at a deemed price of \$0.10 per share. At the date of acquisition, Burrard Bay, a Canadian holding company, held cash in the amount of \$1,000,000 and had no other assets or liabilities. Given that the economic substance of the transaction was that of a financing, with the Company effectively issuing common shares for cash, it has been recorded as such for accounting purposes, with direct costs recorded as a reduction of share capital.

FISCAL 2020

On September 16, 2020, further to the completion of the RTO Transaction, the Company satisfied the primary escrow release conditions of the brokered private placement offering of subscription receipts (the "Brokered Offering") led by Gravititas Securities Inc. (the "Agent"), pursuant to the terms of an agency agreement dated July 29, 2020 (the "Agency Agreement") and the concurrent non-brokered private placement offering of subscription receipts (the "Non-Brokered Offering")(collectively, the "Offerings"), which closed on July 29, 2020. Upon the satisfaction of all related release conditions as agreed by the Company and the Agent, each of the 1,025 subscription receipts issued pursuant to the Offerings, which were issued at a price of \$1,000 per subscription receipt, were deemed to be automatically exchanged without any additional consideration or further action on the part of the holders thereof into one convertible debenture (each a "Convertible Debenture") of the Company. Directors of the Company participated in the private placement for a total amount of \$85,000.

Each Convertible Debenture is an unsecured debt obligation of the Company and consists of a principal amount of \$1,000 bearing interest at the simple rate of 8% per annum and maturing on September 16, 2023 (the "Maturity Date"). Prior to the Maturity Date, and subject to exercise by the Company of an acceleration provision, all the outstanding principal and accrued interest of the Convertible Debentures may be converted into units of the Company (each a "Unit", collectively the "Units") at a price of \$0.20 per Unit, at the sole option of the respective holder of the Convertible Debenture (the "Option"). Unless the Option is exercised prior to the Maturity Date, the Company will subsequently make a cash payment to the holders of the Convertible Debentures to settle the outstanding principal and accrued interest of each respective Convertible Debenture.

Each Unit is comprised of one common share and one-half of one common share purchase warrant (each whole common share purchase warrant, being a "Warrant"). Each Warrant is exercisable to purchase one common share at an exercise price of \$0.30 per common share until September 16, 2023.

The Agent also provided fiscal advisory services pursuant to the terms of a fiscal advisory agreement (the "Fiscal Advisory Agreement") with respect to the Non-Brokered Offering. Pursuant to the Agency Agreement and the Fiscal Advisory Agreement, Molecule Holdings issued an aggregate of 410,000 broker warrants and 40 convertible debentures (the "Compensation Debentures"). Each Compensation Debenture has the same terms as the Convertible Debentures and each broker warrant may be exercised into one Unit at a price of \$0.20 per Unit until September 16, 2023.

Molecule Holdings Inc. (formerly Everton Resources Inc.)

Management's Discussion & Analysis

For the years ended October 31, 2020 and 2019

RECEIPT OF STANDARD PROCESSING LICENCE

On February 28, 2020, Molecule was issued a Standard Processing Licence by Health Canada (the "Licence") in accordance with the Cannabis Act and Cannabis Regulations. The Licence authorizes Molecule to: possess cannabis; produce cannabis, other than obtaining it by cultivating, propagating or harvesting it; and to sell cannabis in accordance with subsection 17(5) of the Cannabis Regulations and in accordance with the conditions of the Licence.

LEASE OF LAND & BUILDING IN THE THOUSAND ISLANDS' REGION OF EASTERN ONTARIO

Effective April 1, 2019, the Company entered into a lease with Thousand Island Farms Inc., a company owned by Andre Audet, a Director of Molecule Holdings, for a parcel of land and a building located in the Thousand Islands' region of Eastern Ontario. The lease has an initial five year term which expires, unless extended, in April 2024. For and during the first and second year of the lease, the base rent is \$60,000, payable in equal monthly instalments of \$5,000. For and during the third and fourth year of the lease, the base rent is \$63,000, payable in equal monthly instalments of \$5,250. For and during the fifth year of the lease, the base rent is \$66,150, payable in equal monthly instalments of \$5,513. Provided that the Company is not in default in the performance of any term of the lease, Molecule has the irrevocable option to purchase, during the lease term, the premises and land for a purchase price equal to \$875,000 if exercised in the first year of the lease, subject to increases in each year of the lease based on the annual Consumer Price Index percentage. The Company paid an amount of \$5,000 in consideration for the grant of the purchase option, which is non-refundable.

GRANTING OF STOCK OPTIONS

On July 2, 2019, 1,000,000 stock options were granted to a consultant of the Company at an exercise price of \$0.10 per share, which vested evenly over a twelve month period and expire on September 17, 2025.

On July 12, 2019, 1,500,000 stock options were granted to directors, officers and employees of the Company at an exercise price of \$0.10 per share, which all vested immediately and expire on July 12, 2024.

On February 8, 2021, 2,600,000 stock options were granted to certain directors, officers, employees and consultants of the Company at an exercise price of \$0.15 per share. The options all vest on the four month anniversary of the grant date and expire on February 8, 2026.

ADVISORY AGREEMENT

Effective June 15, 2019, the Company entered into an advisory agreement with a financial services company (the "Consultant"). Under the agreement, the Consultant served as a strategic advisor to assist the Company in developing a current and ongoing acquisition and capital markets strategy. In consideration for the advisory services, the Company paid the Consultant a monthly retainer in the amount of \$10,000, which was payable in common shares of Molecule on a quarterly basis. The agreement was for a term of twelve months, which ended on June 15, 2020.

Pursuant to the advisory agreement, the Company issued 300,000 common shares on each of September 15, 2019, December 15, 2019, March 15, 2020 and June 15, 2020, at a deemed price of \$0.10 per share.

SHARES ISSUED IN ACCORDANCE WITH EMPLOYMENT AGREEMENT

On December 1, 2019, the Company issued 1,000,000 common shares, at a deemed value of \$0.10 per share, to the Company's Chief Regulatory Officer, in accordance with his terms of employment.

Molecule Holdings Inc. (formerly Everton Resources Inc.)

Management's Discussion & Analysis

For the years ended October 31, 2020 and 2019

ADOPTION OF RESTRICTED SHARE UNIT PLAN AND GRANTING OF RESTRICTED SHARE UNITS

On June 1, 2020, the Company adopted a Restricted Share Unit ("RSU") plan (the "RSU Plan"). The purpose of the RSU Plan is to provide the Company with a share-related mechanism to attract, retain and motivate qualified directors, officers, employees and consultants and to reward them for their contributions toward creating shareholder value through the achievement of the short and long-term goals of the Company.

On June 1, 2020, 1,706,667 RSUs were granted to officers, employees and certain consultants of the Company, of which 1,540,000 vest quarterly over a twelve month period and 166,667 vested upon the date that the Resulting Issuer began trading on the Canadian Securities Exchange. Upon vesting, the RSU holder shall be entitled to receive payment from the Company in settlement of such vested RSUs, in a number of shares, issued from treasury, equal to the number of RSUs being settled.

On September 9, 2020, 750,000 RSUs were granted to certain consultants of the Company, which vest quarterly over a twelve month period.

On January 29, 2021, 4,522,763 RSUs were granted to officers, employees and certain consultants of the Company, which vest over a six month period.

SIGNING OF CANNABIS SUPPLY AGREEMENT

On November 26, 2020, the Company announced the signing of a cannabis supply agreement with Abcann Medicinals Inc., a wholly owned subsidiary of Vivo Cannabis Inc., enabling Molecule to use Vertosa emulsions in its cannabis beverages. Abcann has territory rights to Vertosa emulsion technology and generates the products on site. Vertosa's customized water-compatible solutions are reported to accelerate onset time, increase bioavailability, and improve the taste profile of cannabis-infused products.

COMPLETION OF PRODUCTION-SCALE TEST RUNS OF CANNABIS INFUSED BEVERAGES

On December 23, 2020, the Company announced that it had successfully completed a production-scale test run of cannabis-infused beverages at its licensed facility in Lansdowne, Ontario. The run represented the successful transition from bench-top to full-scale production testing. Production runs begin with water and proceed through filtration, flavoring, cannabis infusion, chilling, gas management, pasteurization and canning. Samples were taken during the course of the production and returned favorable results from testing that was performed in the Company's on-site laboratory.

On January 20, 2021, the Company announced that it had successfully completed another production-scale test run, aimed at refining and finalizing its processes and controls, thereby readying the Company for its sales amendment application and inventory accumulation.

EXTENSION OF WARRANTS

On January 20, 2021, the Company announced that it had extended the expiry date of an aggregate of 1,103,250 previously issued warrants (the "Warrants") for one additional year. 499,750 of the Warrants (4,997,500 pre-consolidation)(the "February 6 Warrants") were originally issued on February 6, 2017 with an original expiry date of February 6, 2019 and were extended in 2019 for an additional two years, to February 6, 2021. 603,500 of the Warrants (6,035,000 pre-consolidation)(the "February 21 Warrants") were originally issued on February 21, 2017 with an original expiry date of February 21, 2019 and were extended in 2019 for an additional two years, to February 21, 2021. The February 6 Warrants and February 21 Warrants will now expire on February 6, 2022 and February 21, 2022, respectively. Each of the 1,103,250 Warrants entitle the holder to purchase a common share of the Company at an exercise price of \$0.70.

Molecule Holdings Inc. (formerly Everton Resources Inc.)

Management's Discussion & Analysis

For the years ended October 31, 2020 and 2019

SALES PARTNERSHIP WITH VORTEX CANNABIS INC.

On January 26, 2021, the Company announced that it had signed a binding term sheet with Vortex Cannabis Inc. ("Vortex") which sets out the terms of a service agreement (the "Service Agreement") whereby Vortex will sell products produced by Molecule to the provincial retailers of cannabis products (the "Provincial Retailers"). The Service Agreement allows Molecule to begin selling its line of cannabis infused beverages throughout Canada, starting initially with Ontario and Quebec. Under the terms of the Service Agreement, Molecule will pay a percentage of revenues to Vortex for its services. The initial term of the Service Agreement covers six months and can be extended as required.

Molecule currently holds a Standard Processing Licence (the "Licence") issued by Health Canada, which allows the Company to produce cannabis-infused products and sell them to other Licensed Producers (LPs). A Standard Processing Licence requires an amendment to allow processors to sell cannabis products directly to Provincial Retailers (the "Sales Amendment"). Rather than waiting until the Sales Amendment is issued, this Service Agreement allows Molecule to bring its line of cannabis-infused beverages to market through Vortex, while completing its own sales amendment application.

SIGNING OF MASTER SUPPLY AGREEMENT WITH THE ONTARIO CANNABIS STORE

On February 3, 2021, the Company announced that its sales partner, Vortex Cannabis Inc. ("Vortex"), had signed a Master Supply Agreement with the Ontario Cannabis Store ("OCS"). The agreement is in relation to 11 products that were previously submitted to the OCS by Molecule and have now been resubmitted with Vortex as the licensed sales partner.

DEBT SETTLEMENT

On January 29, 2021, the Company issued 1,925,300 common shares in settlement of \$288,795 in debt. Directors of the Company received a total of 933,333 common shares in settlement of \$140,000 in debt.

ISSUANCE OF SHARES FOR SERVICES

On January 15, 2021, the Company announced the signing of an agreement with an online marketing company, pursuant to which the Company will pay a total of \$75,000 plus HST, payable in 5 instalments over a twelve month period. The first instalment was due on signing, with subsequent instalments payable quarterly over the twelve month period. All amounts are payable in shares, based on the closing price on each instalment date. On January 26, 2021, the Company issued 135,600 common shares at a price of \$0.125 per common share, in settlement of the first installment of \$16,950 (\$15,000 plus HST).

Molecule Holdings Inc. (formerly Everton Resources Inc.)

Management's Discussion & Analysis

For the years ended October 31, 2020 and 2019

SELECTED FINANCIAL INFORMATION

The following selected financial information is derived from the Company's consolidated financial statements for the years ended October 31, 2020 and 2019, which were prepared in accordance with IFRS:

For the year ended October 31	2020	2019
	\$	\$
Net loss and total comprehensive loss	(3,326,994)	(1,091,247)
Basic and diluted loss per common share	(0.04)	(0.02)

	October 31,	October 31,
As at	2020	2019
	\$	\$
Cash	902,519	2,288,191
Sales taxes receivable	103,081	305,610
Inventory	145,352	-
Marketable securities	239,904	-
Capital assets	3,920,403	2,070,099
Total assets	5,446,981	5,050,528
Total liabilities	2,010,407	732,328

PAYMENT OF DIVIDENDS

The Company's current policy is to retain earnings to finance the development of its business. Therefore, the Company does not anticipate paying cash dividends on the Common Shares in the foreseeable future. The Company's dividend policy will be reviewed from time to time by the Board of Directors in the context of its earnings, financial condition and other relevant factors. Until the time that the Company does pay dividends, which it may never do, shareholders will not be able to receive a return on their Common Shares unless they sell them.

RESULTS OF OPERATIONS

During the year ended October 31, 2020, the Company recorded a net loss and total comprehensive loss of \$3,326,994, as compared to a net loss and total comprehensive loss of \$1,091,247 during the year ended October 31, 2019, an increase of \$2,235,747. The increase for the year ended October 31, 2020 was primarily attributable to variances in the following items: (i) management and consulting fees (ii) salaries and benefits, (iii) professional fees, (iv) stock-based compensation (v) government assistance and (vi) listing expense, as further described below:

- (i) During the year ended October 31, 2020, the Company recorded management and consulting fees of \$637,931, as compared to \$402,285 during the year ended October 31, 2019, an increase of \$235,646. The increase during the year ended October 31, 2020 is mainly due to an increase in the Company's activities, which required additional personnel, including consultants providing services in a number of areas, including but not limited to corporate advisory, logistics, marketing and general administration.
- (ii) During the year ended October 31, 2020, the Company recorded salaries and benefits of \$319,527, as compared to \$209,243 during the year ended October 31, 2019, an increase of \$110,284. The increase during the year ended October 31, 2020 is due to an increase in the Company's activities, which required additional personnel.

Molecule Holdings Inc. (formerly Everton Resources Inc.)

Management's Discussion & Analysis

For the years ended October 31, 2020 and 2019

- (iii) During the year ended October 31, 2020, the Company incurred professional fees of \$285,602, as compared to \$229,059 during the year ended October 31, 2019, an increase of \$56,543. The increase is primarily due to legal fees incurred in connection with the reverse take-over transaction.
- (iv) During the year ended October 31, 2020, the Company recognized stock-based compensation of \$392,504, as compared to \$157,475 during the year ended October 31, 2019, an increase of \$235,029. The increase during the year ended October 31, 2020 is due primarily to the 1,000,000 common shares issued to the Company's Chief Regulatory Officer on December 1, 2019, in accordance with his terms of employment and the vesting of RSUs under a newly adopted RSU plan, which did not exist in 2019.
- (v) During the year ended October 31, 2020, the Company recognized government assistance in the amount of \$96,932, as compared to \$Nil during the year ended October 31, 2019. The government assistance relates to investment tax credits recognized in connection with the government's Scientific Research and Experimental Development program (SR&ED).
- (vi) During the year ended October 31, 2020, the Company recognized listing expenses in the amount of \$1,395,006, as compared to \$Nil during the year ended October 31, 2019. The listing expenses were recognized in connection with the reverse take-over transaction which resulted in the Company's shares being listed on the Canadian Securities Exchange (the "CSE").

SUMMARY OF QUARTERLY RESULTS

The following information has been derived from the eight most recently completed quarters, all presented in accordance with IFRS:

	October 31,	July 31,	April 30,	January 31,
For the three months ended	2020	2020	2020	2020
	\$	\$	\$	\$
Net loss	(2,146,737)	(366,047)	(317,917)	(496,293)
Comprehensive loss	(2,146,737)	(366,047)	(317,917)	(496,293)
Basic and diluted loss per common share	(0.028)	(0.005)	(0.004)	(0.007)

	October 31,	July 31,	April 30,	January 31,
For the three months ended	2019	2019	2019	2019
	\$	\$	\$	\$
Net loss	(357,424)	(417,323)	(140,992)	(175,508)
Comprehensive loss	(357,424)	(417,323)	(140,992)	(175,508)
Basic and diluted loss per common share	(0.005)	(0.006)	(0.004)	(0.013)

The significant increase in the net loss and comprehensive loss during the three month period ended October 31, 2020, as compared to other periods, is due to expenses incurred in connection with the completion of the reverse take-over transaction and the listing of the Company's common shares on the CSE.

LIQUIDITY AND CAPITAL RESOURCES

The Company's liquidity depends on existing cash reserves, supplemented as necessary by equity and/or debt financings. As at October 31, 2020, the Company had a working capital of \$389,236, including cash of \$902,519, marketable securities of \$239,904 and current liabilities of \$1,137,342.

Molecule Holdings Inc. (formerly Everton Resources Inc.)

Management's Discussion & Analysis

For the years ended October 31, 2020 and 2019

During the year ended October 31, 2020, the Company used cash of \$926,465 to fund operating activities.

As the Company's focus has been primarily on the retrofitting of its facility in the Thousand Islands region of Eastern Ontario, obtaining its licence from Health Canada, and on preparing for production of cannabis-infused beverages, it has not generated any operating revenue and has relied exclusively on equity and/or debt financings. The Company may require additional equity and/or debt financing to fund its ongoing operations until it can achieve profitable operations.

OFF-BALANCE SHEET ARRANGEMENTS

As at October 31, 2020 and as of the date of this MD&A, the Company does not have any off-balance sheet arrangements.

PROPOSED TRANSACTIONS

As at the date of this MD&A, there are no proposed asset or business acquisitions or dispositions.

RELATED PARTY TRANSACTIONS

Transactions with key management personnel

Related parties include the Board of Directors and key management personnel, as well as close family members and enterprises that are controlled by these individuals as well as certain persons performing similar functions. Unless otherwise stated, none of these transactions incorporated special terms and conditions and no guarantees were given or received.

Remuneration of directors and key management personnel of the Company was as follows:

For the year ended October 31	2020	2019
	\$	\$
Salaries	95,000	40,000
Consulting fees (1)	140,000	85,000
Stock-based compensation	268,228	67,134
	503,228	192,134

(1) As at October 31, 2020, unpaid consulting fees in the amount of \$139,000 are owed to management and have been included in accounts payable and accrued liabilities (\$5,000 as at October 31, 2019). The amounts owing are unsecured, non-interest bearing and due on demand.

During the year ended October 31, 2020, consulting fees of \$60,000 were paid/payable to Andre Audet, the Company's former CEO and current Director, for services rendered as CEO of the Company (2019 - \$40,000). During the year ended October 31, 2020, Mr. Audet also received \$28,038 in stock-based compensation (2019 - \$22,378).

During the year ended October 31, 2020, salary of \$95,000 was paid/payable to Phil Waddington, the Company's current CEO and former Chief Regulatory Officer ("CRO"), for services rendered as CRO and CEO of the Company (2019 - \$40,000). During the year ended October 31, 2020, Mr. Waddington also received \$128,038 in stock-based compensation (2019 - \$22,378). During the year ended October 31, 2019, Mr. Waddington also received consulting fees of \$5,000.

Molecule Holdings Inc. (formerly Everton Resources Inc.)

Management's Discussion & Analysis

For the years ended October 31, 2020 and 2019

During the year ended October 31, 2020, consulting fees of \$80,000 were paid/payable to Brendan Stutt, the Company's former CFO, for services rendered as CFO of the Company. (2019 - \$40,000). Mr. Stutt also received \$56,076 in stock-based compensation (2019 - \$22,378).

During the year ended October 31, 2020, David Reingold, now a Director of the Company, received \$56,076 in stock-based compensation (2019 - \$Nil).

FINANCIAL INSTRUMENTS, RISK MANAGEMENT AND CAPITAL MANAGEMENT*Financial instruments*

The Company's financial instruments consist of cash, marketable securities, other receivables, accounts payable and accrued liabilities, convertible debt and other long-term liabilities. The fair value of the Company's financial instruments approximates their carrying value due to their short-term nature.

The classification of financial instruments is as follows:

	October 31, 2020	October 31, 2019
	\$	\$
Financial assets		
Amortized cost		
Cash	902,519	2,288,191
Other receivables	-	2,874
Fair value through profit or loss		
Marketable securities	239,904	-
Total financial assets	1,142,423	2,291,065
Financial liabilities		
Amortized cost		
Accounts payable and accrued liabilities	(1,094,133)	(516,949)
Convertible debt	(697,625)	-
Other long-term liabilities	(40,000)	-
Total financial liabilities	(1,831,758)	(516,949)

Risk management

The Company thoroughly examines the various financial risks to which it is exposed and assesses the impact and likelihood of those risks. These risks include credit risk, liquidity risk and market risk. Where material, these risks are reviewed and monitored by the Board of Directors.

(i) Credit risk

Credit risk is the risk of an unexpected loss if a party to its financial instruments fails to meet its contractual obligations. The Company's financial assets exposed to credit risk are primarily composed of cash. The Company's cash is held at reputable financial institutions with high external credit ratings. It is Management's opinion that the Company is not exposed to significant credit risk.

None of the Company's financial assets are secured by collateral or other credit enhancements.

Molecule Holdings Inc. (formerly Everton Resources Inc.)

Management's Discussion & Analysis

For the years ended October 31, 2020 and 2019

Management considers that all the above financial assets that are not impaired or past due for each of the reporting dates are of good credit quality. There are no financial assets that are past due but not impaired for the periods presented.

(ii) Liquidity risk

Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they come due. The Company's liquidity and operating results may be adversely affected if its access to the capital markets is hindered, whether as a result of a downturn in stock market conditions generally or matters specific to the Company. The Company regularly evaluates its cash position to ensure preservation and security of capital as well as liquidity. The Company's accounts payable and other liabilities generally have contractual maturities of less than 30 days and are subject to normal trade terms.

(iii) Market risk

The Company holds shares in a publicly listed company in the mineral exploration industry. The Company is exposed to market risk regarding these shares as unfavorable market conditions could result in the disposal at less than their value at October 31, 2020. As at October 31, 2020, the value of these listed shares was \$239,904. At October 31, 2020, had the price for these publicly listed shares been 10% lower, the comprehensive loss for the year would have been \$23,990 greater. Conversely, had the price been 10% higher, the comprehensive loss would have been \$23,990 less.

Capital management

The Company's objectives when managing capital are to safeguard the Company's ability to continue as a going concern, to meet its capital expenditures for its continued operations, and to maintain a flexible capital structure which optimizes the cost of capital within a framework of acceptable risk. The Company manages its capital structure and adjusts it in light of changes in economic conditions and the risk characteristics of the underlying assets. To maintain or adjust its capital structure, the Company may issue new shares through equity offerings or return capital to shareholders. The Company is not subject to externally imposed capital requirements.

Management reviews its capital management approach on an ongoing basis. There have been no changes to the Company's capital management approach during the years ended October 31, 2020 and 2019.

CHANGE IN ACCOUNTING POLICIES

The Company has not had any changes in accounting policies, other than the adoption of new mandatory standards under IFRS as well as amendments to existing standards, for the years ended October 31, 2020 and 2019.

INHERENT RISK FACTORS

You should carefully consider the following risks and uncertainties in addition to other information in this MD&A in evaluating Molecule Holdings and its business before making any investment decision. These risks and uncertainties are not the only ones the Company is facing. Additional risks and uncertainties not presently known to the Company, or that it currently deems immaterial, may also impair its operations. If any such risks actually occur, the business, financial condition, liquidity and results of the Company's operations could be materially adversely affected. The risk factors described below should be carefully considered by readers, including investors considering a purchase of securities of the Company.

An investment in securities of the Company should only be made by persons who can afford a significant or total loss of their investment.

Molecule Holdings Inc. (formerly Everton Resources Inc.)

Management's Discussion & Analysis

For the years ended October 31, 2020 and 2019

The Company's business requires compliance with regulatory or agency proceedings, investigations and audits

The Company's business requires compliance with many laws and regulations, specifically Canadian cannabis laws that are still in the early stages and subject to unexpected changes. Failure to comply with these laws and regulations could subject the Company or the businesses in which it invests to regulatory or agency proceedings or investigations and could also lead to damage awards, fines and penalties. The Company may become involved in a number of government or agency proceedings, investigations and audits. The outcome of any regulatory or agency proceedings, investigations, audits, and other contingencies could harm the Company's reputation, require the Company to take, or refrain from taking, actions that could harm its operations or require the Company to pay substantial amounts of money, harming its financial condition. There can be no assurance that any pending or future regulatory or agency proceedings, investigations and audits will not result in substantial costs or a diversion of management's attention and resources or have a material adverse impact on the Company's business, financial condition and results of operation.

Licensing requirements for cannabis companies in Canada

The market for cannabis and cannabis derivative products in Canada is regulated by the *Cannabis Act* and *Cannabis Regulations*. Health Canada is the primary regulator of the cannabis industry as a whole. There is no guarantee that the Company will obtain all the necessary licences or approvals required for its business. In addition, failure to comply with the requirements of any licence or any failure to maintain such licence would have a material adverse impact on the business, financial condition and operating results of the Company.

There is no assurance that the Company will turn a profit or generate immediate revenues

The Company has no history of earnings or cash flow from operations and the Company may not generate material revenue or achieve self-sustaining operations for several years, if at all. There is no assurance as to whether the Company will be profitable, earn revenues, or pay dividends. The Company anticipates that it will incur substantial expenses relating to the development and initial operations of its investments and business. The payment and amount of any future dividends will depend upon, among other things, the Company's results of investments, operations, cash flow, financial condition, and operating and capital requirements. There is no assurance that future dividends will be paid, and, if dividends are paid, there is no assurance with respect to the amount of any such dividends.

Requirements for Further Financing and Dilution

The Company may not have sufficient financial resources to undertake all of the activities as currently planned. The Company may need to obtain further financing, whether through debt financing, equity financing or other means. To obtain such funds the Company may sell additional securities, the effect of which could result in substantial dilution of the equity interests of the holders of the Company Shares. There can be no assurance that the Company will be able to raise the balance of the financing required or that such financing can be obtained without substantial dilution to shareholders or that the terms of such financing will be favourable. Failure to obtain additional financing on a timely basis could cause the Company to reduce or terminate its operations.

The Company has a limited operating history

The Company will not have a record of achievement to be relied upon. The Company's operations are subject to all the risks inherent in the establishment of a new business enterprise, including a lack of operating history. The Company cannot be certain that its investment strategy or development of the Company's business will be successful. The likelihood of the Company's success must be assessed in consideration of the problems, expenses, difficulties, complications and delays frequently encountered in connection with the establishment of any business. If the Company fails to address any of those risks or difficulties adequately, the business will likely suffer.

Molecule Holdings Inc. (formerly Everton Resources Inc.)

Management's Discussion & Analysis

For the years ended October 31, 2020 and 2019

The Company may be vulnerable to unfavorable publicity or consumer perception

Cannabis and cannabis derivatives industries are highly dependent upon consumer perception regarding the safety, efficacy and quality of the cannabis produced. Consumer perception can be significantly influenced by scientific research or findings, regulatory investigations, litigation, media attention and other publicity regarding the consumption of cannabis products. There can be no assurance that future scientific research, findings, regulatory proceedings, litigation, media attention or other research findings or publicity will be favorable to the cannabis market or any particular product, or consistent with earlier publicity. Future research reports, findings, regulatory proceedings, litigation, media attention or other publicity that are perceived as less favorable than, or that question, earlier research reports, findings or publicity could have a material adverse effect on the demand for cannabis and on the business, results of operations, financial condition and cash flows of the Company. Further, adverse publicity reports or other media attention regarding the safety, efficacy and quality of cannabis in general, or associating the consumption of cannabis with illness or other negative effects or events, could have such a material adverse effect. Such adverse publicity reports or other media attention could arise hindering market growth and state adoption due to inconsistent public opinion and perception of the medical-use and adult-use cannabis industry.

The cannabis industry is subject to increasing competition

There is potential that the Company will face intense competition from other companies, some of which can be expected to have longer operating histories and more financial resources and production and marketing experience than the Company. Because of the early stage of the industry in which the Company will operate, the Company will face additional competition from new entrants. If the number of users of marijuana products in Canada increases, the demand for products will increase and competition will become more intense, as current and future competitors begin to offer an increasing number of diversified products and pricing strategies. To remain competitive, the Company will require a continued high level of investment in research and development, marketing, sales and client support. The Company may not have sufficient resources to maintain research and development, marketing, sales and client support efforts on a competitive basis which could materially and adversely affect the business, financial condition and results of operations of the Company.

Reliance on Management

The success of the Company is dependent upon the ability, expertise, judgment, discretion and good faith of its senior management. While employment agreements or management agreements are customarily used as a primary method of retaining the services of key employees, these agreements cannot assure the continued services of such employees. Any loss of the services of such individuals could have a material adverse effect on the Company's business, operating results, financial condition or prospects.

Ongoing Costs and Obligations

The Company expects to incur significant ongoing costs and obligations related to its investment in infrastructure and growth and for regulatory compliance, which could have a material adverse impact on the Company's results of operations, financial condition and cash flows. In addition, future changes in regulations, more vigorous enforcement thereof or other unanticipated events could require extensive changes to the Company's operations, increased compliance costs or give rise to material liabilities, which could have a material adverse effect on the business, results of operations and financial condition of the Company.

Product Liability

Upon becoming a producer or distributor of products designed to facilitate cannabis ingestion by humans, the Company would face an inherent risk of exposure to product liability claims, regulatory action and litigation if such products are alleged to have caused significant loss or injury. In addition, tampering by unauthorized third parties or product contamination with respect to the cannabis used in such products may impact the risk

Molecule Holdings Inc. (formerly Everton Resources Inc.)

Management's Discussion & Analysis

For the years ended October 31, 2020 and 2019

of injury to consumers. Previously unknown adverse reactions resulting from human consumption of cannabis alone or in combination with other medications or substances could occur. As a supplier and/or producer and/or distributor and/or retailer of products designed to facilitate the consumption of cannabis, the Company may be subject to various product liability claims, including, among others, that the cannabis product caused injury or illness, included inadequate instructions for use or included inadequate warnings concerning possible side effects or interactions with other substances. A product liability claim or regulatory action against the Company could result in increased costs, could adversely affect the Company's reputation with its clients and consumers generally, and could have a material adverse effect on the business, results of operations, financial condition or prospects of the Company. There can be no assurances that the Company will be able to maintain product liability insurance on acceptable terms or with adequate coverage against potential liabilities. Such insurance is expensive and may not be available in the future on acceptable terms, or at all. The inability to maintain sufficient insurance coverage on reasonable terms or to otherwise protect against potential product liability claims could prevent or inhibit the commercialization of the Company's potential products or otherwise have a material adverse effect on the business, results of operations, financial condition or prospects of the Company.

Product Recalls

Manufacturers and distributors of products are sometimes subject to the recall or return of products for a variety of reasons, including product defects, such as contamination, unintended harmful side effects or interactions with other substances, packaging safety and inadequate or inaccurate labeling disclosure. Such recalls can cause unexpected expenses of the recall and any legal proceedings that might arise in connection with the recall. This can cause loss of a significant amount of sales. In addition, a product recall may require significant management attention. Although the Company will have detailed procedures in place for testing its products or require that third parties do the same where applicable, there can be no assurance that any quality, potency or contamination problems will be detected in time to avoid unforeseen product recalls, regulatory action or lawsuits. Additionally, if one of the Company's brands were subject to recall, the image of that brand and the Company could be harmed. Additionally, product recalls can lead to increased scrutiny of operations by applicable regulatory agencies, requiring further management attention and potential legal fees and other expenses.

Product Approvals

The Company may require advance approval of its products from authorities in the applicable jurisdiction. While the Company intends to follow the guidelines and regulations of each applicable local jurisdiction in preparing products for sale and distribution, there is no guarantee that such products will be approved to the extent necessary. If the products are approved, there is a risk that any jurisdiction may revoke its approval for such products based on changes in laws or regulations or based on its discretion or otherwise. If any of the Company's products are not approved or any existing approvals are rescinded, there is the potential to lead to a material adverse effect on the Company's business, financial condition, results of operations or prospects.

Product Exchanges, Returns and Warranty Claims

If the Company is unable to maintain or cause the maintenance of an acceptable degree of quality control of products it produces or distributes, the Company may incur costs associated with the exchange and return of the products as well as servicing its customers for warranty claims. Any of the foregoing on a significant scale may have a material adverse effect on the Company's business, results of operations and financial condition.

Results of Future Clinical Research

Research in Canada and internationally regarding the medical benefits, viability, safety, efficacy, dosing and/or social acceptance of cannabis or isolated cannabinoids (such as CBD and THC) remains in early stages. There have been relatively few clinical trials on the benefits of cannabis or isolated cannabinoids (such as CBD and THC). Although the Company believes that the articles, reports and studies support their beliefs

Molecule Holdings Inc. (formerly Everton Resources Inc.)

Management's Discussion & Analysis

For the years ended October 31, 2020 and 2019

regarding the medical benefits, viability, safety, efficacy, dosing and/or social acceptance of cannabis, future research and clinical trials may prove such statements to be incorrect, or could raise concerns regarding, and perceptions relating to, cannabis. Given these risks, uncertainties and assumptions, holders or prospective purchasers of the Company Shares should not place undue reliance on such articles and reports. Future research studies and clinical trials may draw opposing conclusions or reach negative conclusions regarding the medical benefits, viability, safety, efficacy, dosing, social acceptance or other facts and perceptions related to cannabis, which could have a material adverse effect on the demand for the Company's products with the potential to lead to a material adverse effect on the Company's business, financial condition, results of operations or prospects.

Reliance on Key Inputs

The business of the Company would be dependent on a number of key inputs and their related costs including raw materials and supplies related to product development and manufacturing operations. Any significant interruption or negative change in the availability or economics of the supply chain for key inputs could materially impact the Company's business, financial condition, and results of operations or prospects. Some of these inputs may only be available from a single supplier or a limited group of suppliers. If a sole source supplier was to go out of business, the Company might be unable to find a replacement for such source in a timely manner or at all. If a sole source supplier were to be acquired by a competitor, that competitor may elect not to sell to the Company in the future. Any inability to secure required supplies and services or to do so on appropriate terms could have a materially adverse impact on the business, financial condition, results of operations or prospects of the Company.

Dependence on Suppliers and Skilled Labour

The ability of the Company to compete and grow will be dependent on it having access, at a reasonable cost and in a timely manner, to skilled labour, equipment, parts and components. No assurances can be given that the Company will be successful in maintaining its required supply of skilled labour, equipment, parts and components. It is also possible that the final costs of the major equipment contemplated by the Company's capital expenditure plans may be significantly greater than anticipated by the Company's management, and may be greater than funds available to the Company, in which circumstance the Company may curtail, or extend the timeframes for completing, its capital expenditure plans. This could have an adverse effect on the Company's business, financial condition, results of operations or prospects.

Litigation

The Company may become party to litigation from time to time in the ordinary course of business which could adversely affect its business. Should any litigation in which the Company becomes involved be determined against the Company, such a decision could adversely affect the Company's ability to continue operating and the market price for the Company Shares. Even if the Company is involved in litigation and wins, litigation can redirect significant company resources.

Operating Risks and Insurance

The Company's operations will be subject to hazards inherent in the cannabis industry, such as equipment defects, malfunction and failures, natural disasters which result in fires, accidents and explosions that can cause personal injury, loss of life, suspension of operations, damage to facilities, business interruption and damage to or destruction of property, equipment and the environment, labour disputes, and changes in the regulatory environment. These risks could expose the Company to substantial liability for personal injury, wrongful death, property damage, pollution, and other environmental damages. The frequency and severity of such incidents would affect operating costs, insurability and relationships with customers, employees and regulators.

Molecule Holdings Inc. (formerly Everton Resources Inc.)

Management's Discussion & Analysis

For the years ended October 31, 2020 and 2019

The Company will continuously monitor its operations for quality control and safety. However, there are no assurances that the Company's safety procedures will always prevent such damages. Although the Company will maintain insurance coverage that it believes to be adequate and customary in the industry, there can be no assurance that such insurance will be adequate to cover its liabilities. In addition, there can be no assurance that the Company will be able to maintain adequate insurance in the future at rates it considers reasonable and commercially justifiable. The occurrence of a significant uninsured claim, a claim in excess of the insurance coverage limits then maintained by the Company, or a claim at a time when it is not able to obtain liability insurance, could have a material adverse effect on the Company, the Company's ability to conduct normal business operations and on the Company's business, financial condition, results of operations and cash flows in the future.

Dilution

The Company may enter into financings or other transactions involving the issuance of securities of the Company which may be dilutive to the other shareholders and any new equity securities issued could have rights, preferences and privileges superior to those of holders of Company Shares.

Changes in Laws, Regulations and Guidelines

The Company's operations will be subject to various laws, regulations, guidelines and licensing requirements. While the Company is expected to be in compliance with all such laws, any changes to such laws, regulations, guidelines and policies due to matters beyond the control of the Company could have a material adverse effect on the Company's business, results of operations and financial condition.

Constraints on Marketing Products

The development of the Company's business and operating results may be hindered by applicable restrictions on sales and marketing activities imposed by government regulatory bodies. The regulatory environment in Canada limits companies' abilities to compete for market share in a manner similar to other industries. If the Company is unable to effectively market its products and compete for market share, or if the costs of compliance with government legislation and regulation cannot be absorbed through increased selling prices for its products, the Company's sales and results of operations could be adversely affected.

COVID-19 Outbreak

Since the emergence of a novel strain of coronavirus ("COVID-19"), in or about December 2019, the highly contagious virus has spread across the world. On March 11, 2020, the World Health Organization declared the outbreak of COVID-19 a global pandemic. Since that time in response to the outbreak, governmental authorities in Canada and internationally have implemented various measures with the aim of preventing or limiting further spread of COVID-19. These measures, which have included travel restrictions, border closures, non-essential business closures, quarantines, self-isolations, and social distancing, have, among other things, resulted in widespread business, employment and economic disruptions. The global pandemic continues to evolve and the ultimate impact of the COVID-19 outbreak is highly uncertain.

The continued global spread of COVID-19 could have an adverse impact on the business, operations and financial results of the Company, including with respect to issues related to labour, processing and supply chain. Molecule Holdings is implementing or will implement precautionary measures, which would not have otherwise been implemented prior to the COVID-19 outbreak, at its facility to ensure the safety of its personnel, suppliers and consumers, which may adversely impact the Company's labour productivity and its supply chains. For example, mandatory or voluntary self-quarantines may limit the staffing of the Company's facility. In addition, it's possible that the COVID-19 pandemic may adversely affect Molecule Holdings' ability to successfully market and sell its products. Although the opposite may be true, sales volumes of cannabis-infused products may be adversely impacted by consumer "social distancing" behaviours. Continued spread of COVID-19 globally could also lead to a deterioration of general economic conditions including a possible

Molecule Holdings Inc. (formerly Everton Resources Inc.)

Management's Discussion & Analysis

For the years ended October 31, 2020 and 2019

national or global recession. Due to the unpredictability and scale of the effects of COVID-19, Molecule Holdings is unable to accurately estimate the impact or level of materiality of COVID-19 on its business, operations or financial results. The Company will monitor the situation in order to assess any possible adverse impact on its business, supply chain and customers on an ongoing basis and to determine which measures, if any, will be taken to mitigate such adverse impact.

CRITICAL ACCOUNTING ESTIMATES

See Note 2 to the Company's consolidated financial statements for the years ended October 31, 2020 and 2019.

NEW ACCOUNTING POLICIES ISSUED BUT NOT YET EFFECTIVE

See Note 2 to the Company's consolidated financial statements for the years ended October 31, 2020 and 2019.

OUTSTANDING SHARE DATA

Common shares and convertible securities outstanding at February 18, 2021, consist of:

<u>Security</u>	<u>Expiry date</u>	<u>Range of exercise price</u>	<u>Securities outstanding</u>
		\$	#
Common shares	-	-	90,291,278
Warrants	Up to September 16, 2023	0.20 - 0.70	1,718,250
Stock options	Up to September 17, 2025	0.10 - 1.30	3,560,000
Restricted share units	-	-	4,818,125

In addition to the securities noted in the above table, there are also 1,065 convertible debentures outstanding, issued in connection with the private placement which closed on July 29, 2020. Each convertible debenture consists of a principal amount of \$1,000 and may be converted into units of the Company (each a "Unit" or collectively the "Units") at a price of \$0.20 per Unit. Each Unit is comprised of one common share and one-half of one common share purchase warrant exercisable at \$0.30. See Corporate Development Highlights section for further details.

ADDITIONAL INFORMATION AND CONTINUOUS DISCLOSURE

Additional information on the Company is available on SEDAR (www.sedar.com).